LH and FSH: Evaluating the Pituitary-Gonadal Axis and Fertility
Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) control reproductive function in both genders. Evaluating these markers assesses pituitary health and fertility, and cash pay keeps your family planning data private.
This article describes blood diagnostics, public health reporting mandates, and record containment options. It is not clinical diagnostic advice or treatment instruction. Cash pay shields your commercial insurance profile but does not circumvent state infectious disease reporting laws for positive results.
How LH and FSH Coordinate Reproductive Health
Produced by the pituitary gland, Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) act on the gonads to control reproductive function. In men, LH stimulates the Leydig cells in the testes to produce testosterone, while FSH stimulates spermatogenesis (sperm production). In women, LH triggers ovulation, while FSH stimulates follicle development in the ovaries. Together, these markers evaluate the health of your Hypothalamic-Pituitary-Gonadal (HPG) axis.
Evaluating Ovarian Reserve, Menopause, and Male Hypogonadism
In women, elevated FSH levels are an early indicator of declining ovarian reserve or menopause. In men, measuring LH and FSH is essential to distinguish between primary hypogonadism (testicular failure, where LH/FSH are elevated) and secondary hypogonadism (pituitary dysfunction, where LH/FSH are low or normal despite low testosterone). These tests provide a detailed look at fertility and hormone health.
Securing Your Family Planning History
Reproductive health and family planning data are incredibly sensitive. Filing these markers under commercial insurance creates a permanent medical trail that insurer systems can analyze. Utilizing cash-pay laboratory networks allows you to evaluate your HPG axis and track fertility in absolute privacy.
Frequently Asked Questions
Q: What does high FSH indicate in women?
A: High FSH levels (typically above 25 mIU/mL) on Day 3 of the menstrual cycle indicate declining ovarian reserve, perimenopause, or menopause.
Q: Why do bodybuilders test LH and FSH?
A: Anabolic steroid use suppresses pituitary function, dropping LH and FSH to zero. Bodybuilders track these markers to monitor pituitary recovery during Post-Cycle Therapy (PCT).